Vertex Pharmaceuticals Incorporated reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported revenue was USD 2,334.3 million compared to USD 1,984.1 million a year ago. Net income was USD 930.5 million compared to USD 851.9 million a year ago. Basic earnings per share from continuing operations was USD 3.63 compared to USD 3.3 a year ago. Diluted earnings per share from continuing operations was USD 3.59 compared to USD 3.28 a year ago.
For the nine months, revenue was USD 6,628 million compared to USD 5,501.8 million a year ago. Net income was USD 2,503.1 million compared to USD 1,572 million a year ago. Basic earnings per share from continuing operations was USD 9.78 compared to USD 6.08 a year ago. Diluted earnings per share from continuing operations was USD 9.68 compared to USD 6.03 a year ago.